These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38880557)

  • 1. Injectable Buprenorphine: An Opportunity to Improve Treatment Access for Youth With Opioid Use Disorder.
    Calihan JB; Bagley SM
    J Adolesc Health; 2024 Jul; 75(1):13-14. PubMed ID: 38880557
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 4. Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation.
    Stancliff S; Greene D; Zucker HA
    Am J Public Health; 2019 Dec; 109(12):1678-1679. PubMed ID: 31693402
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement.
    Williams AR; Mauro CM; Huber B; Chiodo L; Crystal S; Samples H; Olfson M
    Am J Psychiatry; 2024 May; 181(5):457-459. PubMed ID: 38706334
    [No Abstract]   [Full Text] [Related]  

  • 6. Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.
    Scholzen E; Zeng AM; Schroeder KM
    Adv Anesth; 2019 Dec; 37():65-86. PubMed ID: 31677660
    [No Abstract]   [Full Text] [Related]  

  • 7. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 8. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
    Vidyasagar N; Bunting SR; Arora VM; Ari M
    JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
    Schmuhl KK; Golec A; Ebersole AM
    J Adolesc Health; 2024 Jul; 75(1):200-202. PubMed ID: 38402472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic.
    Straub A; Pastor A; Lloyd-Jones M; O'Neill H; Bonomo Y
    Drug Alcohol Rev; 2021 May; 40(4):681-682. PubMed ID: 32898928
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder.
    Davis CS; Carr DH; Glenn MJ; Samuels EA
    Ann Emerg Med; 2021 Jul; 78(1):102-108. PubMed ID: 33781607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating prescription opioid dependence.
    Ruetsch C
    JAMA; 2014 Sep; 312(11):1145-6. PubMed ID: 25226480
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescription opioid dependence: the clinical challenge.
    Newman RG
    JAMA Psychiatry; 2014 Mar; 71(3):338. PubMed ID: 24599244
    [No Abstract]   [Full Text] [Related]  

  • 16. Buprenorphine MAT as an Imperfect Fix.
    Mund B; Stith K
    J Law Med Ethics; 2018 Jun; 46(2):279-291. PubMed ID: 30147005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 18. Buprenorphine offers a way to rise from the ashes of addiction.
    Newcomb A
    J Fam Pract; 2021 Sep; 70(7):317. PubMed ID: 34818160
    [No Abstract]   [Full Text] [Related]  

  • 19. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy.
    Berry M; Kiefer MK; Hinely KA; Bowden H; Jordan A; Vilensky M; Rood KM
    Obstet Gynecol; 2024 Jun; 143(6):815-818. PubMed ID: 38574367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.